---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-100231"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:49:34.907173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY

## Summary
- Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
- Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.
- Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.
- Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.
- CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales.

## SEC filing metadata
- accession: 0001213900-24-100231
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/0001213900-24-100231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390024100231/ea0221824-8k_emma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-100231
- JSON: https://secwatch.observer/filing/0001213900-24-100231.json
- Plain text: https://secwatch.observer/filing/0001213900-24-100231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.